Amarin | AMRN - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.84B 205M 2026-09
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Amarin USD 18.97M 1.03M 2025-12
AstraZeneca USD 4.07B 1.73B 2026-09
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
DBV Technologies USD 15.8M 2.4M 2026-09
GlaxoSmithKline GBP 2.16B 39M 2026-09
Halozyme Therapeutics USD 58.24M 1.24M 2026-09
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 154M 23.92M 2026-09
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Novartis USD 3.08B 163M 2026-09